Gavin Hirst
About Gavin Hirst
Gavin Hirst is the Chief Scientific Officer at Atomwise, leading their drug discovery efforts since September 2022, with over 30 years of experience in the field.
Gavin Hirst Chief Scientific Officer at Atomwise
Gavin Hirst took on the role of Chief Scientific Officer at Atomwise in September 2022. In this position, he is responsible for spearheading all drug discovery initiatives within the company. Leveraging his extensive background, Hirst brings a wealth of expertise in advancing small molecule assets from the research phase to clinical trials and beyond.
Gavin Hirst Drug Discovery Experience
With over 30 years in the field of drug discovery, Gavin Hirst has accumulated a substantial breadth of knowledge working in both large pharmaceutical companies and biotech firms. His experience spans multiple therapeutic areas, including immunology and oncology. Hirst has successfully advanced numerous small molecule assets through various stages of development, showcasing his capability in leading cutting-edge drug discovery projects.
Gavin Hirst Previous Leadership Roles
Before joining Atomwise, Gavin Hirst was the interim Chief Scientific Officer at Turning Point Therapeutics, playing a pivotal role until its acquisition by Bristol-Myers Squibb (BMS) in June 2022 for $4.1 billion. His career also includes significant leadership roles at major pharmaceutical companies such as Janssen, Takeda, and Abbvie, further emphasizing his robust experience in the industry.
Gavin Hirst Education and Post-Doctoral Studies
Gavin Hirst earned his Ph.D. in organic chemistry from the University of Southampton. Following his doctoral studies, he completed post-doctoral research at the University of California, Irvine. His strong academic background provides a solid foundation for his work in drug discovery and scientific leadership.